The Postoperative Adjuvant Therapy of Gefitinib for High Risk Stage Ib NSCLC Patients With EGFR Sensitive Mutation, an Open, Paired, Non-interventional, Multi-center Clinical Study
Phase of Trial: Phase IV
Latest Information Update: 21 Dec 2017
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Dec 2017 Status changed from suspended to discontinued.
- 02 Nov 2016 Status changed from recruiting to suspended.
- 25 Aug 2015 New trial record